23,790 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Bought by Bryce Point Capital LLC

Bryce Point Capital LLC acquired a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 23,790 shares of the biopharmaceutical company’s stock, valued at approximately $601,000.

A number of other hedge funds have also recently modified their holdings of the business. EverSource Wealth Advisors LLC lifted its position in Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 878 shares during the period. Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics during the fourth quarter valued at approximately $81,000. KBC Group NV lifted its holdings in shares of Celldex Therapeutics by 79.1% during the fourth quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 1,647 shares during the last quarter. AlphaQuest LLC boosted its position in shares of Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,705 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new stake in shares of Celldex Therapeutics in the 4th quarter worth approximately $273,000.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $17.38 on Thursday. The firm has a market capitalization of $1.15 billion, a P/E ratio of -6.76 and a beta of 1.76. Celldex Therapeutics, Inc. has a one year low of $16.40 and a one year high of $47.00. The business has a fifty day moving average of $21.49 and a 200 day moving average of $25.81.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CLDX shares. Morgan Stanley assumed coverage on Celldex Therapeutics in a report on Thursday, March 20th. They issued an “overweight” rating and a $46.00 target price on the stock. The Goldman Sachs Group cut their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. UBS Group started coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $44.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $54.33.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.